Linking a Single Dominant Antibody to HIT: A Novel Study Led by Ishac Nazy, Donald Arnold, and John G. Kelton
Mark Crowther, Distinguished University Professor and Chair, Department of Medicine at McMaster University, shared on LinkedIn:
”McMaster’s Department of Medicine: New Insight into a Life-Threatening Blood Disorder, Led by McMaster Researchers
A paper published last week in the New England Journal of Medicine has reshaped how we understand heparin-induced thrombocytopenia (HIT)—a serious reaction to a widely used blood thinner.
Researchers from McMaster Faculty of Health Sciences and the McMaster University Department of Medicine have found that, contrary to decades of belief, a single monoclonal antibody is responsible for triggering HIT.
This key discovery suggests the condition is not a polyclonal immune response, as previously thought, but rather driven by one dominant antibody—an insight that could significantly improve diagnostic precision and lead to more targeted therapies.
The study was led by Dr. Ishac Nazy, PhD, Professor in the Department of Medicine and John G. Kelton Chair in Immunological Blood Disorders and and Dr Donald Arnold.
Their team includes investigators from the McMaster Platelet Immunology Laboratory and the Michael G. DeGroote Centre for Transfusion Research.
Dr. Nazy notes: ‘Our findings correct a long-standing misunderstanding of HIT and point toward more accurate and safer testing methods.’
This work underscores McMaster’s continued leadership in translational research—bringing molecular discoveries closer to clinical application.”
Find more insights here.
Stay updated on the emerging in the field of platelet disorders with Hemostasis Today.
-
Sep 9, 2025, 23:00Blood Podcast Alert: LSD1 Inhibitors in SCD, Ruxolitinib+Dex in HLH, Low VWF Insights
-
Sep 9, 2025, 15:47AFib: A Hidden Stroke Risk
-
Sep 9, 2025, 07:56Mortality Risk in Thrombotic Thrombocytopenic Purpura․ Insights from Laboratory Biomarkers
-
Sep 9, 2025, 06:21Vincentius Liong on Nanorobot Swarms vs Blood Clots
-
Sep 9, 2025, 05:53Noel Hiney Highlights the Value of Blood Donation and Community Support
-
Sep 10, 2025, 08:20Flora Peyvandi on Caplacizumab: Which VWF Assays Truly Measure Treatment Effectiveness?
-
Sep 10, 2025, 03:36International Journal of Stroke: Rising Incidence of Stroke in Young Adults
-
Sep 9, 2025, 19:11John Fanikos Shares Greg Piazza's Presentation On The Results of The HI-Pro Trial
-
Sep 9, 2025, 08:15Taha Ahmed Highlights Rare Case: LV Fibroelastoma Mimicking Thrombus Leading to Takotsubo
-
Sep 9, 2025, 08:14JAMA Neurology: MRI Aneurysm Wall Enhancement Predicts Risk of Intracranial Aneurysm Growth or Rupture
-
Sep 9, 2025, 20:15Linking a Single Dominant Antibody to HIT: A Novel Study Led by Ishac Nazy, Donald Arnold, and John G. Kelton
-
Sep 8, 2025, 14:24Von Willebrand Factor as a Therapeutic Target․ From Development to Clinical Application
-
Sep 8, 2025, 02:35Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
-
Sep 7, 2025, 14:16Mary Kiige: Biological Hemoglobin Oxygen Carrier as a Lifesaving Oxygen Bridge
-
Sep 7, 2025, 14:13Breakthrough in Blood: Cécile Denis and INSERM Team Develop Nanobody Therapy for Type 1 VWD
-
Sep 9, 2025, 10:34James Douketis Receives the 2025 Distinguished Service Award in General Internal Medicine!
-
Sep 9, 2025, 08:07Hemophilia Federation of America Launches ‘Blood Brothers’ Podcast for Men With Bleeding Disorders
-
Sep 9, 2025, 04:57World Thrombosis Day 2025: Louise Bannon Invites Donations and Partnerships
-
Sep 8, 2025, 15:10Michael Makris on WHO’s Essential Medicines List Update: A Win for the Global Haemophilia Community
-
Sep 8, 2025, 14:26European Haemophilia Consortium Marks World PT Day: Physiotherapy Empowers People with Bleeding Disorders